SCHEMBL6124019

SCHEMBL6124019

CC1(C)CNc2ccc(-c3ccc(C(F)(F)F)cc3)nc2O1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.36
KIF11 P52732 2/20 0.36
NISCH Q9Y2I1 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
POLB P06746 1/20 0.35
RAB9A P51151 1/20 0.35
ATM Q13315 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TRPV3 Q8NET8 9/20 0.34
NOTUM Q6P988 1/20 0.34
KDM1A O60341 1/20 0.33
MAOB P27338 1/20 0.33
TOP1 P11387 1/20 0.33
S1PR1 P21453 1/20 0.33
RAD51 Q06609 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1396407 0.78 KIF11 (0.38) KIF11NISCHKDM4ENPC1POLB
SCHEMBL1396655 0.76 NOTUM (0.40) PGRKIF11KDM4ENPC1POLB
SCHEMBL6123995 0.76 KIF11 (0.45) PGRKIF11NISCHKDM4E
SCHEMBL17026832 0.72 TRPV1 (0.36) PGRKIF11KDM4EMEN1KMT2A
SCHEMBL12653762 0.69 BACE1 (0.46) KDM4EKDM1AMAOB
SCHEMBL9147420 0.69 MAPT (0.39) PGRKIF11KDM4EMEN1KMT2A
SCHEMBL5428163 0.68 KIF11 (0.48) PGRKIF11NISCH
SCHEMBL6123983 0.66 PARP1 (0.42) KIF11NISCHKDM4ENPC1POLB
SCHEMBL1812256 0.65 KDM1A (0.46) KDM4EPOLBMEN1KMT2ANOTUM
SCHEMBL5674161 0.65 TRPV3 (0.40) KIF11NISCHKDM4ENPC1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946212-B2 Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2015-02-03 US disclosed
US-8946212-B2 Annelated N-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals SANOFI-AVENTIS (FR) 2015-02-03 US disclosed
EP-2288604-B1 ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-01-08 EP disclosed
US-20120122853-A1 ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
US-20120122853-A1 ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2012-05-17 US disclosed
WO-2009149820-A1 ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122853-A1 ANNELATED N-HETEROCYCLIC SULFONAMIDES WITH OXADIAZOLONE HEADGROUP, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS PPARD, PPARA, PPARG PGR 1578/4885KIF11 3595/4885NISCH 300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.